221 related articles for article (PubMed ID: 23292309)
1. Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients.
van de Luijtgaarden AC; Versleijen-Jonkers YM; Roeffen MH; Schreuder HW; Flucke UE; van der Graaf WT
Target Oncol; 2013 Dec; 8(4):253-60. PubMed ID: 23292309
[TBL] [Abstract][Full Text] [Related]
2. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome profiling of Ewing sarcomas - treatment resistance pathways and IGF-dependency.
Chen Y; Hesla AC; Lin Y; Ghaderi M; Liu M; Yang C; Zhang Y; Tsagkozis P; Larsson O; Haglund F
Mol Oncol; 2020 May; 14(5):1101-1117. PubMed ID: 32115849
[TBL] [Abstract][Full Text] [Related]
5. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Vishwamitra D; Wang Y; Maywald RL; Buford AS; Fokt I; Skora S; Wang J; Naing A; Lazar AJ; Rohren EM; Daw NC; Subbiah V; Benjamin RS; Ratan R; Priebe W; Mikos AG; Amin HM; Ludwig JA
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27576731
[TBL] [Abstract][Full Text] [Related]
6. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway.
Li J; You T; Jing J
Cell Prolif; 2014 Apr; 47(2):152-60. PubMed ID: 24517182
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.
Scotlandi K; Manara MC; Hattinger CM; Benini S; Perdichizzi S; Pasello M; Bacci G; Zanella L; Bertoni F; Picci P; Serra M
Eur J Cancer; 2005 Jun; 41(9):1349-61. PubMed ID: 15913990
[TBL] [Abstract][Full Text] [Related]
8. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
10. β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.
Zheng H; Shen H; Oprea I; Worrall C; Stefanescu R; Girnita A; Girnita L
Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20620-5. PubMed ID: 23188799
[TBL] [Abstract][Full Text] [Related]
11. IGF signaling pathway analysis of osteosarcomas reveals the prognostic value of pAKT localization.
van de Luijtgaarden AC; Roeffen MH; Leus MA; Flucke UE; Schreuder BH; van der Graaf WT; Versleijen-Jonkers YM
Future Oncol; 2013 Nov; 9(11):1733-40. PubMed ID: 24156333
[TBL] [Abstract][Full Text] [Related]
12. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
[TBL] [Abstract][Full Text] [Related]
14. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Naing A; LoRusso P; Fu S; Hong DS; Anderson P; Benjamin RS; Ludwig J; Chen HX; Doyle LA; Kurzrock R
Clin Cancer Res; 2012 May; 18(9):2625-31. PubMed ID: 22465830
[TBL] [Abstract][Full Text] [Related]
15. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.
Subbiah V; Naing A; Brown RE; Chen H; Doyle L; LoRusso P; Benjamin R; Anderson P; Kurzrock R
PLoS One; 2011 Apr; 6(4):e18424. PubMed ID: 21494688
[TBL] [Abstract][Full Text] [Related]
16. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects.
Benini S; Manara MC; Cerisano V; Perdichizzi S; Strammiello R; Serra M; Picci P; Scotlandi K
Int J Cancer; 2004 Jan; 108(3):358-66. PubMed ID: 14648701
[TBL] [Abstract][Full Text] [Related]
17. Picropodophyllin inhibits the growth of Ewing's sarcoma cells through the insulin‑like growth factor‑1 receptor/Akt signaling pathway.
Wu YT; Wang BJ; Miao SW; Gao JJ
Mol Med Rep; 2015 Nov; 12(5):7045-50. PubMed ID: 26323364
[TBL] [Abstract][Full Text] [Related]
18. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.
Herrero-Martín D; Osuna D; Ordóñez JL; Sevillano V; Martins AS; Mackintosh C; Campos M; Madoz-Gúrpide J; Otero-Motta AP; Caballero G; Amaral AT; Wai DH; Braun Y; Eisenacher M; Schaefer KL; Poremba C; de Alava E
Br J Cancer; 2009 Jul; 101(1):80-90. PubMed ID: 19491900
[TBL] [Abstract][Full Text] [Related]
19. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T; Singh AS; Kiyuna T; Dry SM; Li Y; James AW; Igarashi K; Kawaguchi K; DeLong JC; Zhang Y; Hiroshima Y; Russell T; Eckardt MA; Yanagawa J; Federman N; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
Oncotarget; 2016 Jul; 7(30):47556-47564. PubMed ID: 27286459
[TBL] [Abstract][Full Text] [Related]
20. Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma.
Garofalo C; Mancarella C; Grilli A; Manara MC; Astolfi A; Marino MT; Conte A; Sigismund S; Carè A; Belfiore A; Picci P; Scotlandi K
Mol Endocrinol; 2012 Sep; 26(9):1603-16. PubMed ID: 22798295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
